<?xml version="1.0" encoding="UTF-8"?>
<p>Owing to the recent developments pertaining to the management of chronic HCV infection with DAA therapy at primary healthcare level, it is imperative for physicians to be aware of the emerging resistance to these drugs in order to avoid their misuse.</p>
